U.S. market Closed. Opens in 11 hours 59 minutes

KROS | Keros Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue151.00KN/A20.10MN/A10.00M10.00M
Cost of Revenue815.00K1.61M898.00K605.00K17.35MN/A
Gross Profit-664.00K-1.61M19.20M-605.00K-7.35M10.00M
Operating Expenses167.69M107.71M76.47M44.20M20.00M11.32M
Selling, General & Admin34.83M27.52M21.33M12.80M3.18M1.58M
Research & Development135.26M87.27M55.14M33.86M17.38M10.11M
Other Operating Expenses-206.00K-7.08M-356.00K-2.46M-558.00K237.00K
Operating Income-169.94M-114.79M-56.37M-46.66M-10.56M-1.69M
Other Expenses / Income14.55M10.11M-360.00K1.12M-1.77M237.00K
Before Tax Income-152.99M-104.68M-56.73M-45.53M-12.34M-1.08M
Income Tax Expenses-206.00K1.00K2.01M-172.00K8.00K257.00K
Net Income-152.99M-104.68M-58.74M-45.36M-12.34M-1.33M
Interest ExpensesN/A1.00K4.00K6.00K8.00K-6.00K
Basic Shares Outstanding29.45M25.24M23.33M15.51M8.88M8.88M
Diluted Shares Outstanding29.45M25.24M23.33M15.51M8.88M8.88M
EBITDA-166.93M-104.68M-56.73M-45.53M-9.80M-1.17M
EBITDA Margin-110,550.99%0.00%-282.23%0.00%-97.97%-11.68%
EBIT-153.20M-104.68M-56.73M-45.53M-12.33M-1.08M
EBIT Margin-101,455.63%0.00%-282.23%0.00%-123.28%-10.84%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙